Streetbeat News

Products Services

DCPH

Deciphera Pharmaceuticals reported a preliminary unaudited Q4 2023 net product revenue of approximately $46M for Qinlock, marking a 40% increase year-over-year. The company also announced plans to submit a New Drug Application for Vimseltinib in Q2 2024 and a Marketing Authorisation Application in Q3 2024 for the treatment of Tenosynovial Giant Cell Tumor. Additionally, Deciphera is preparing for a Phase 2 study of Vimseltinib for Chronic Graft Versus Host Disease to begin in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:17 pm

JOBY

Joby Aviation, Inc. has partnered with Clay Lacy Aviation to install the first electric air taxi charger at John Wayne Airport in Southern California. This development is a step towards the commercialization of Joby's electric air taxis.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:14 pm

IONS

Ionis Pharmaceuticals presented its 2023 achievements and anticipated milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference. The company's progress and future plans are likely to influence investor sentiment and the valuation of its stock.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:13 pm

HLVX

HilleVax and Kangh have entered into an exclusive license agreement for the development and commercialization of a hexavalent VLP norovirus vaccine candidate outside of China. This partnership could potentially enhance HilleVax's product pipeline and market reach, while providing Kangh with licensing revenues and a share in the global market, excluding China.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:13 pm

NRIX

Nurix Therapeutics has announced its key objectives and anticipated milestones for the year 2024. The company is expected to provide updates on its progress and achievements throughout the year, which may include clinical trial results, regulatory filings, partnerships, or other significant developments. Investors will be closely monitoring Nurix's progress towards these goals as they can have a substantial impact on the company's performance and stock valuation.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:11 pm

TVTX

Travere Therapeutics reported receiving 459 new patient start forms for Filspari (Sparsentan) in Q4 2023. Preliminary net product sales for Filspari reached $15M in Q4 and totaled $30M since its commercial launch in February 2023.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:10 pm

CABA

Cabaletta Bio has received additional FDA Fast Track Designations for its investigational drug CABA-201, aimed at treating dermatomyositis and systemic sclerosis. The company has previously obtained FDA clearance for IND applications for CABA-201 in various autoimmune conditions such as SLE, myositis, SSc, and gMG.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:05 pm

HARP

MRK

Merck & Co Inc (NYSE:MRK) is in talks to acquire Harpoon Therapeutics Inc (NASDAQ:HARP) for an estimated $700 million, at a proposed price of around $23 per share. This acquisition is part of Merck's strategy to diversify its oncology portfolio beyond its top-selling drug Keytruda. Harpoon's lead candidate, HPN328, has shown promising results in early-stage trials for small-cell lung cancer. MRK's stock closed at $117.20, while HARP's shares surged 99.8% to $21.08 in premarket trading.

Portfolio Pulse from Vandana Singh

January 08, 2024 | 12:04 pm

CROX

Crocs Inc. forecasts a revenue growth of 3% to 5% for 2024 over 2023, with the Crocs brand expected to grow 4% to 6% and the HEYDUDE brand projected to be flat to slightly up.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:04 pm

CEVA

Ceva, Inc. (NASDAQ:CEVA) has expanded its AI ecosystem for the NeuPro-M NPU IP by forming partnerships with Visionary.ai and ENOT.ai, targeting automotive and Edge AI applications. Visionary.ai enhances camera capabilities in low-light and HDR scenarios, while ENOT.ai's role in the partnership was not detailed in the article.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:03 pm